Cefpodoxime: Difference between revisions
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Bronchitis (chronic), actue bacterial infection: 200 mg q 12 h for 10 days | |||
*Pharyngitis/Tonsillitis: 100 mg q 12 h for 5-10 days | |||
*Acute community acquired pneumonia: 200 mg q 12 h for 14 days | |||
*Acute rhino sinusitis: 200 mg q 12 h for 10 days | |||
*Skin and soft tissue infection: 400 mg q 12 h for 14 days | |||
*Urinary tract infection, uncomplicated: 100 mg q 12 h for 7 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revision as of 14:28, 6 June 2016
General
- Type: 3rd generation cephalosporin
- Dosage Forms: tablet (100,200), suspension (50 mg/5ml, 100 mg/5ml)
- Common Trade Names: Cefopodoxine Proxetil
Adult Dosing
- Bronchitis (chronic), actue bacterial infection: 200 mg q 12 h for 10 days
- Pharyngitis/Tonsillitis: 100 mg q 12 h for 5-10 days
- Acute community acquired pneumonia: 200 mg q 12 h for 14 days
- Acute rhino sinusitis: 200 mg q 12 h for 10 days
- Skin and soft tissue infection: 400 mg q 12 h for 14 days
- Urinary tract infection, uncomplicated: 100 mg q 12 h for 7 days
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: